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The level of MnSOD is directly correlated with grade of brain tumours of
neuroepithelial origin
M Landriscina', F Remiddil, F Ria', B Palazzottil, ME De Leo', M Iacoangeli2, R Rosselli2,
M Scerrati2 and T Galeotti'
'Institute of General Pathology and 2Neurosurgery, Catholic University, Largo F. Vito 1, 00168 Rome, Italy.
Summary The oxy-radical scavenger enzyme manganese superoxide dismutase (MnSOD) may act in the
capacity of a tumour-suppressor gene. To address the issue of its role in tumour transformation and
progression in vivo, we evaluated the content of this enzyme in 33 brain tumours of neuroepithelial origin with
different degrees of differentiation (WHO grade II-IV) by means of Western blot and immunohistology. Our
results show that immunoreactive MnSOD increases in a direct relationship with tumour grade and is therefore
inversely correlated with differentiation. The increase is induced at a pretranscriptional level and is apparently
specific to brain tumours of neuroepithelial origin. Approximately 30% of grade IV tumours display low levels
of MnSOD content, and preoperative radiotherapy and brachytherapy result in low amounts of enzyme. Based
upon these observations, we suggest that MnSOD cannot be considered a classical tumour-suppressor gene.
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The mitochondrial scavenger enzyme manganese superoxide
dismutase (MnSOD) is one of the three SODs that catalyse
the dismutation of superoxide radicals to oxygen and
hydrogen peroxide in eukaryotes, the other two being
cytosolic CuZnSOD and extracellular CuZnSOD. While
cytosolic CuZnSOD is a constitutive enzyme, MnSOD is an
inducible protein, and the expression of its gene is regulated
by the redox state of the cell and by cytokines, among which
a dominant role is played by IL-1 and TNF-oa (Hassan, 1988;
Harris, 1992; Wong, 1995).
In experimental rat hepatocarcinomas, the MnSOD
content decreases following an inverse relationship with the
degree of differentiation (Galeotti et al., 1989). A decrease in
MnSOD content has also been reported in human neoplastic
pathology, both in in vitro cell lines and in in vivo tumours
(Sun, 1990). Furthermore, the steps of human hepatocarci-
nogenesis are accompanied by a progressive decrease of both
CuZnSOD and MnSOD. According to these observations, a
reduction in MnSOD has been looked at as a key point for
malignant transformation and/or tumour progression, and it
has been suggested that MnSOD could behave as a tumour-
suppressor protein by preventing oxy-radical-mediated DNA
damage (Sun, 1990; Bravard et al., 1992a, b; Church et al.,
1993; Li et al., 1995).
In contrast with this hypothesis, conflicting results have
been reported for lung cancers (lizuka et al., 1984).
Moreover, measurement of MnSOD by ELISA showed that
its levels were increased in the sera of 12 out of 23 patients
suffering from ovarian tumours (Ishikawa et al., 1990) and in
8 out of 12 patients suffering from neuroblastoma
(Kawamura et al., 1992).
Brain tumours of neuroepithelial origin are classified on
the basis of histological characteristics and of predominant
cell type. Presence and degree of nuclear atypias, atypical
mitosis, cell polymorphism, vascular proliferation and
necrosis, together with the mitotic index, determine the
histological grading. These tumours offer an interesting
model for research, dealing with the processes of tumour
initiation and progression. In most cases, the histological
grade of malignancy is linked to their prognosis, as happens
in experimental tumours. Better differentiated tumours often
evolve into more malignant forms, demonstrating an example
of progression of neoplastic disease. It has also been reported
that TNF-a can be secreted by human glioblastoma cell lines,
by some glioblastomas and by peritumoral brain tissue (Nitta
et al., 1994). Therefore, it was interesting to examine the role
and regulation of MnSOD in the group of brain tumours of
glial origin as they offer an in vivo model in which different
degrees of differentiation, progression of disease and TNF-a
secretion can be found.
A further point of interest in such a study is the fact that
some low-grade tumours have an unexpectedly accelerated
evolution towards high-grade, highly malignant tumours. One
goal of current research in neurosurgery is to identify
histological and/or biochemical parameters that may help in
highlighting such a group within the good-prognosis, low-
grade group of malignancies. This type of marker would
allow identification of patients with less favourable prognosis
who would benefit from more aggressive treatment. Several
biological markers have been studied in this respect. Some of
these markers are related to growth rate and cell cycle, such
as labelling index (Franzini et al., 1994), PCNA (Korkolo-
poulou et al., 1993), BrdU (Labrousse et al., 1991) and Ki-67
(Morimura et al., 1991). Others refer more directly to tumour
biology, such as amplification of the EGF receptor gene
(Hurtt et al., 1992; Schlegel et al., 1994), loss of
heterozygosity (LOH) for p53 (Fults et al., 1992; von
Deimling et al., 1992; Rasheed et al., 1994), LOH for
chromosome 19q (Ritland et al., 1995) and annexin II
expression (Roseman et al., 1994). However, the field is still
open to further contributions as no marker has yet proved to
be an effective identifier. Therefore, it would also make sense
to evaluate in a preliminary way whether the MnSOD can be
studied as a metabolic marker of progression. If so, it might
be used in a study dedicated to prove its effectiveness in
identifying the group of low-grade tumours that are at a
higher risk of accelerated progression of the disease.
The main goal of the experiments that we report in the
present paper was to further our knowledge on the role of
MnSOD in tumour transformation and progression in an in
vivo human model. We asked whether variation of MnSOD
can be observed in tumours of glial origin with respect to
normal controls, and if these variations are linked to the
degree of differentiation and, if so, which molecular
mechanism is responsible for them.
In order to address these issues, we analysed 38 brain
tumours, 33 of neuroepithelial origin and five of extraneural
origin. We assessed the amount of the MnSOD protein in the
neoplastic tissues and evaluated the expression of its mRNA.
These results were subsequently compared with the
histological grade.
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Between May 1994 and October 1995, specimens from 33
brain tumours of neuroglial origin were collected (see Table
I). Twenty-one patients were male (M) and 12 female (F); the
mean age was 49.4 years (range 25 -75 years). Sixteen
tumours were glioblastomas (designated from now on as
grade IV according to WHO classification) [M/F, 7/9; mean
age 56.4 (range 32-75) years], four were anaplastic
astrocytomas and the others included one anaplastic
oligoastrocytoma and two anaplastic oligodendrogliomas
(collectively referred to as grade III, WHO) [M/F, 7/1;
mean age 40 (range 27-64) years], four astrocytomas, one
pleiomorphic xanthoastrocytoma, three oligodendrogliomas
and two oligoastrocytomas (hereafter grade II, WHO) [M/F,
7/2; mean age 42.4 (range 25-60) years]. All tumours were
localised in the hemispherical white matter, and the
intraoperative localisation of the tumours was obtained by
means of ultrasonography.
In addition, samples from five brain tumours of extraglial
origin (three metastasis, one non-Hodgkin lymphoma (NHL),
one haemangiopericytoma) and four samples of tissue from
normal, non-infiltrated areas were analysed. Five patients
(three grade IV and two grade III) underwent either pre-
operative radiotherapy (RT) (3) or brachytherapy (2) shortly
before the removal of tumour.
All the samples were intraoperative specimens, obtained
during surgical removal of the brain tumour. They were
divided into 125 mm3 pieces and immediately frozen in liquid
nitrogen and stored at -80°C. Samples were thawed only
once and were analysed 15 -30 days after collection; one
piece was used for histology, one for Western blot (WB)
analysis and one for immunohistology (IH) and 'mirror'
conventional histology. For eight specimens (two normal
cortexes, one grade II, one grade III and four grade IV
tumours), an aliquot was used for RNA preparation.
The MnSOD studies were performed double blind with
respect to histology, clinical status and degree of surgical
removal.
Of the 33 samples from tumours of neuroepithelial origin,
22 were examined both by WB and IH, two by WB only and
nine by IH alone.
Monoclonal antibody
The preparation and maintenance of monoclonal antibody
(MAb) 35.8 has previously been described (Ria et al., 1993).
Table I Characteristics of patients
KPfa Diame-
ter
No. Histology Age Sex Pre Post cm
GradeII
I Astrocytoma 44 M 80 80 9
2 Oligodendroglioma 46 M 90 80 4
3 Oligoastrocytoma 30 M 90 60 5
4 Oligodendroglioma 45 M 80 80 4
5 Pleomorphic xanthoastrocytoma 36 M 80 80 5
6 Oligodendroglioma 30 M 80 80 3.5
7 Astrocytoma 60 M 90 90 7
8 Astrocytoma 50 F 90 90 4.5
9 Oligoastrocytoma 47 M 90 90 5
10 Gemistocytic astrocytoma 25 F 90 90 6
Grade III
1 Ib Anaplastic oligoastrocytoma 32 M 90 90 3.5
12 Anaplastic astrocytoma 45 M 90 90 3
13c Anaplastic oligodendroglioma 27 F 70 70 7
14 Anaplastic oligodendroglioma 46 M 70 70 5
15 Anaplastic gemistocytic astrocytoma 39 M 90 90 3.5
16 Anaplastic astrocytoma 64 M 50 60 8
17 Anaplastic astrocytoma 36 M 70 60 3.5
GradeIV
18 Glioblastoma 67 M 80 90 5
19 Glioblastoma 46 M 70 50 6
20 Multifocal glioblastoma 59 F 80 80 2.5
21 Glioblastoma 74 F 40 50 5.5
22 Multifocal glioblastoma 63 F 60 40
23 Glioblastoma 53 M 70 80 6
24c Glioblastoma 55 M 80 80 4
25 Glioblastoma 45 F 80 60 3
26 Glioblastoma 32 M 80 80 5
27 Glioblastoma 57 F 60 60 6
28C Glioblastoma 45 M 80 80 6.5
29 Glioblastoma 49 F 70 70 4
30b Glioblastoma 57 F 70 40 4
31 Glioblastoma 66 F 70 50 5
32 Glioblastoma 59 M 50 50 9
33 Glioblastoma 75 F 80 dec. 4.8
Extraglial origin
34 Haemangiopericytoma 17 F 70 90 9
35 NHL 51 F 70 60 3.5
36 Metastasis of large bowel adenocarcinoma 61 F 80 80 4
37 Metastasis of lung adenocarcinoma 34 F 70 70 3.5
38 Metastasis of lung adenocarcinoma 57 M 40 dec. 9
aKarnowski performance index before (pre) and after (post) surgery. bBrachytherapy.cPreoperative
radiotherapy. dec., Patient deceased.MnSOD increase in brain tumours
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We have also reported that this MAb is able to recognise
human MnSOD in WB and immunofluorescence, and that it
was able to detect 80 pg of human protein (Ria et al., 1994)
in WB.
Immunohistology
Immediately before use, slices were cut and fixed in acetone-
methanol (50%, v/v) for 10 min at4°C. Slices were then washed
three times by immersion in phosphate-buffered saline (PBS)
0.1 M for 30 min, followed by a 15 min incubation with protein
blocking agent (Immunon-Lipshaw, Pittsburgh, PA, USA).
After a fast wash in PBS (0.1 M), the preparations were
incubated at room temperature with the supernatant of MAb
35.8, concentrated 50-fold by means of Minicon concentrators
(Amicon) or with normal mouse serum diluted 1: 80 in PBS
(0.1 M) as control. Two hours later the slices were washed by
immersion in 0.1 M PBS for 10 min, and incubated for 30 min
with goat anti-mouse antibody conjugated with FITC (for
immunofluorescence, Coulter) or with alkaline phosphatase
(Sigma) diluted according to manufacturer's indications. After
a final wash, BCIP/NBT (20 mg ml 'in water, Sigma) was
added for 30 min. The reaction was stopped after 30 min by a
very fast wash in water.
To exclude the possibility that the immuno-histological
analysis had been performed on areas that were either more
differentiated or necrotic, or even on peripheral normal brain,
we re-evaluated the histology of slices sequential to the ones
on which the immunostaining had been performed.
Immunoprecipitation
Tumour specimens were homogenised in potassium phos-
phate buffer (200 Mg wet weight ml-') (as described in
Galeotti et al., 1989, except in our case no dialysis was
performed). Protein concentration was determined using the
biuret method. The homogenates were then incubated with
the supernatant of the MAb (250 Ml mg-' protein for a total
of 4 mg of protein) for 6 days at 4°C under continuous
rolling. An aliquot of 30 jIl of Sepharose conjugated with
goat anti-mouse antiserum was added and the mixture was
incubated at 37°C under continuous agitation. One hour later
it was centrifuged for 10 min at 14 000 r.p.m., and the pellets
recovered were resuspended in 15 pl of sample buffer for
SDS-PAGE and WB analysis.
Western blot
The method for immunoblot detection of MnSOD has
previously been described (Ria et al., 1993). In brief, SDS
gel-electrophoresis was performed on a 12.5% gel. Immuno-
precipitated samples were loaded and separated proteins were
horizontally electroluted onto nitrocellulose paper. Immuno-
blot detection of MnSOD was performed with the super-
natant of 35.8 hybridoma, seeded at 106 cells ml-' and
incubated at 37°C and 5% carbon dioxide for 30 days, using
a phosphatase-labelled goat anti-mouse IgG antiserum
(Sigma) as detection system. The amount of MnSOD was




















Figure 1 Western blot of immunoprecipitates of homogenates from normal human liver, normal human brain and esemplificative
tumours. The arrows indicate the band corresponding to monomeric MnSOD. Lane 1 in a and lane 6 in b show the 27.5 and
18.5 kDa MW standard (Biorad).
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monomeric MnSOD (26 kDa apparent molecular weight). As
a positive control, a sample immunoprecipitated from human
normal liver was also run. This gave a reproducible intensity
of the band corresponding to MnSOD. To exclude inter-
sample variations, most samples were run at least twice.
RNA isolation
RNA was isolated as according to Chomezynski et al. (1987)
by RNAs extraction and purification solution (Bioprobe).
RNA concentrations were determined spectrophotometrically
by absorbance at 260 nm.
Quantitative analysis of mRNAs
Total RNA for the analysis of MnSOD specific mRNA was
size fractionated by formaldehyde-agarose (1.5%) gel
electrophoresis and blotted onto nylon membrane. Blots
were prehybridised for 5 h and hybridised to MnSOD cDNA
overnight at 42°C. The cDNA probe was radiolabelled with
I
$.*.i;s'
[oc-32P]dCTP using a multiprime DNA labelling system
(Amersham).
Measurement of MnSOD activity
The method published in Martin et al. (1987) was followed.
In brief, SOD activity was assayed on the homogenised
samples from the value giving 50% inhibition of haematox-
ylin autoxidation to haematein and was monitored at 560 nm
and at pH 7.5 and 25°C, using a standard curve obtained
with the purified bovine blood enzyme. MnSOD activity was
measured in the presence of 1.5 mM cyanide.
Interpretation of the results
The results were expressed on a semiquantitative scale in
comparison with human liver (+ + + + in both WB and IH)
and normal glia (+ in WB and - in IH). In IH when
evaluating the observation, intermediate values were given





Figure 2 Immunohistochemical detection of MnSOD in tumours no. 3 (a) -, bar =40/M, 14 (b) (+ +, bar=62.5tM), 16 (c)
(+ + +, bar=62.5jiM) and 21 (d) (+ + + +, bar=40jiM). (e) Immunostaining of the boundary region between tumour positive for
MnSOD (+ + +) and peritumoral normal brain (patient 16). bar=40/iM.slice or for the more intense staining of isolated cells or of a
few areas only (excluding the necrotic areas). For both WB
and IH, the results were scored by three independent
observers. Examples of the weighing of the results are
shown in Figures 1 and 2. When patients were studied with
both approaches, as the observations were evaluated
independently. A similar method was used to evalute the
mRNA levels.
The MnSOD content was divided into four classes: 1 (+
WB and/or - and + IH); 2 (+ + WB and/or + + IH); 3
(+ + + WB and/or + ++ IH); 4 (+ + + + WB and/or
+ + + + IH).
Results
We reported previously that the MAb 35.8, raised against a
synthetic peptide encompassing amino acids 184-198 of rat
MnSOD, is able to recognise human MnSOD in both native
and denatured form (Ria et al., 1994). Using this MAb, we
first developed a method able to detect MnSOD in normal
glia by immunoprecipitation followed by WB. The result is
MnSOD increase in brain tumours
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shown in Figure la. According to our previous observations
obtained in rat, the normal glia and brain have low but
detectable physiological levels of protein, possibly near the
lower limit of detection of our MAb, and therefore we used
approximately 0.1 ng of MnSOD in 4 mg of total proteins.
We next examined a panel of brain tumours of glial origin
and found that some of them showed a remarkable increase
in MnSOD content. Based upon this observation, we
analysed the panel of 33 brain glial tumours, plus 5 brain
tumours of extraneural origin, listed in Table I. In order to
have further information and to be able to study smaller
samples such as biopsies, we also used the same antibody for
immunohistological studies, using both fluorescent and
peroxidase conjugated detection systems. The results are
listed in Table II and are shown in Figures 1 and 2.
Figure 1 shows the WB analysis of some representative
tumours; the arrows indicate the band corresponding to
monomeric MnSOD. In some of the tumours reported in
Figure 1, two extra bands can be seen; the one slower than
monomeric MnSOD represents the cytosolic precursor of the
protein (Ria et al., 1993; Kawaguchi et al., 1989), while the
faster one represents products of the degradation occurring in
Table II MnSOD content evaluated by means of western blot and immunohistology
















































































6 Metastasis of large bowel
adenocarcinoma
7 Metastasis of lung adenocarcinoma
8 Metastasis of lung adenocarcinoma
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vivo (ME De Leo, manuscript in preparation). As described
in the Materials and methods section, the amount of MnSOD
was evaluated according to the intensity of the band
corresponding to monomeric MnSOD.
In order to assess the information obtained using the two
different techniques, we compared the results obtained using
WB and IH in 22 patients that were independently evaluated
with both methods. Results are shown in Figure 3 and
describe the correlation of the values observed. As expected,
there is a highly significant (P=0.001) correspondence of the
values estimated with these approaches in all of the types of
tumour (Pearson's rho coefficient=0.6369, n=22, df=6),
with the only exception of two glioblastomas that display a
remarkable difference in the amount of protein detected by
WB (4+) compared with that detected by IH (0- +).
The MnSOD content was evaluated with respect to
tumour grading. When both WB and IH data were
available, the highest value was used. Results are shown in
Figure 4 and demonstrate a significant correlation between
tumour grading and MnSOD content P=0.005, chi-square =
18.80, df=6). No correlation was found between MnSOD
content and either sex (chi-square= 1.01, P=0.80) or age
(Student t-test, P=0.102).
Most grade II tumours (7/10) had levels of MnSOD
indistinguishable from the ones observed in the normal
counterpart. On the opposite side of the spectrum, 9/16
glioblastomas have a very high MnSOD content (class 3 and
4), similar to the one observed in liver. Grade III tumours
behave in an intermediate way showing a gaussian-like
distribution around level 3. Glioblastomas have a profile
characterised by a double peak; 7/16 show 'low' (1-2,
peaking at 2) levels of immunoreactive protein.
Preoperative RT and brachytherapy may account for the
low amount of detectable MnSOD as found in some
tumours. In fact two patients (one grade III and one grade
IV) were evaluated as belonging to class 1, and three (1 grade
III and 2 grade IV) as belonging to class 2. In these samples,
we observed a low number of cells, not always clearly
neoplastic, with large areas of necrosis. However, even if
these patients are not considered, it is evident that there is a
consistent group of grade IV tumours (4/13 30%) showing
low levels of MnSOD.
We measured the activity of the enzyme in tumours nos. 2,
3 (grade II), 11 (grade III), 18, 19, 20, 21 (grade IV) (not
shown). Even in those tumours that displayed very high levels
of immunoreactive protein, no increase of the enzymatic
activity was found with respect to normal brain or grade II
tumours (see Discussion).
We then monitored the quantity of mRNA specific for









Figure 3 Correlation of MnSOD content evaluated by means of
Western blot and immunohistology. Each symbol represents one
patient.
III and Figure 5) show a tight correlation between mRNA
and protein content and suggest that the increase of MnSOD
content is due to higher levels of specific mRNA.
We also evaluated the content of MnSOD in five brain
tumours of extraglial origin, and the results are shown in
Figure 6. Four out of the five neoplasias tested (one NHL,
one haemangiopericytoma and two metastases from different
lung adenocarcinomas) showed low levels of MnSOD both in
WB and IH, while 1 metastasis from colon adenocarcinoma
showed a + + + amount of MnSOD in WB and a - level in
IH.
As patient no. 26 suffered a malignant relapse of an
anaplastic astrocytoma, and patient no. 33 died within 30
days after surgery, we report in Table IV the survival of 14
out of 16 patients suffering from glioblastoma. The subjects
are listed according to the amount of MnSOD, together with
their Karnowski performance index, diameter, residual






Figure 4 Correlation of MnSOD content and WHO grade of
brain tumours of neuroepithelial origin. Grade II tumours are
presented as open bars, grade III by shaded bars and grade IV by
black bars.
Table III Messenger RNA for MnSOD in brain tumours
MnSOD




14 Anaplastic oligodendroglioma 3 + +
19 Glioblastoma 4 + + + +
20 Glioblastoma 3 + +
21 Glioblastoma 4 + + + +
22 Glioblastoma 4 + + + +
-28 S
18 S
1 2 3 4 5 6 7 8
Figure 5 Northern blot hybridisation of MnSOD cDNA with
total RNA from glioblastomas (grade IV) no. 19 (lane 1), two
normal human brain (lanes 2 and 6), glioblastoma no. 21 (lanes 3
and 5), glioblastoma no. 22 (lanes 4 and 8) and anaplastic
oligodendroglioma (grade III) no. 14 (lane 7).
*Grade'll tumours
- EGrade III tumours
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Figure 6 MnSOD content of five brain tumours of extraglial
origin, evaluated by means of both Western blot and
immunohistology.
Discussion
The aim of our experiments was to address some questions
about the role of MnSOD in tumour transformation and
progression: can we describe variations in the scavenger
enzyme MnSOD content that depend on the tumour grade of
anaplasia in human in vivo models?; which mechanisms
sustain these variations?; is it possible that MnSOD behaves
as a tumour-suppressor protein?
To approach these problems, we chose brain tumours of
neuroepithelial origin as a model in which we could find
various degrees of histological, biological and clinical
differentiation, progression of disease and secretion of the
cytokines involved in the regulation of the gene encoding for
MnSOD.
We previously reported that MnSOD content follows an
inverse relationship with the tumour malignancy in experi-
mental rat hepatocarcinomas (Galeotti et al., 1989), and
other authors reported a tight link between MnSOD decrease
and the processes of tumour transformation and progression
in several human models, both in vitro and in vivo (Sun,
1990). We previously reported that a metastasis from an
adenocarcinoma of the colon was negative for MnSOD
within a strongly positive normal liver tissue (Ria et al., 1994)
and in the present report we show that four out of five non-
glial brain tumours also display very low levels of the enzyme
under study. Thus, all these results would support a general
view that MnSOD has somehow to decrease during tumour
transformation or progression (Sun, 1990). The most
noteworthy exceptions reported so far have been the
increases of MnSOD levels in the sera of approximately
50% of the patients affected by ovarian cancer and
neuroblastoma (Ishikawa et al., 1990; Kawamura et al.,
1992). These observations may also be explained by a high
death rate in tumour tissues, rather than by increased
MnSOD content alone. In fact, immunocytochemical
detection was performed only sporadically, and in the same
reports it was observed that chemotherapy of neuroblastomas
increases these levels (Kawamura et al., 1992).
The data that we report in the present paper, attest that
MnSOD, when studied in brain tumours of neuroepithelial
origin, exhibits a behaviour opposite to that expected. In fact,
our findings indicate that the cellular content of immunor-
eactive MnSOD increases in tandem with histological
grading, i.e. it is in a direct relationship with loss of
differentiation and with biological and clinical malignancy.
We can therefore rule out the hypothesis that the gene
encoding for MnSOD is a tumour-suppressor gene according
to the classical definition. However, the reasons for this
inverse comportment remain to be explained. We suggest two
hypotheses that may reconcile this model with the others.
The first hypothesis stems from the observation that the
enzyme activity does not increase proportionally with the
immunoreactive protein. A similar lack of correlation
between enzyme activity and immunoreactive protein was
also reported for lung adenocarcinomas (lizuka et al., 1984).
The difference between protein and enzymatic activity may be
dependent on the lack of metal co-factor; it has been reported
that manganese content decreases in a number of tumours,
compared with their tissue of origin (Ling et al., 1990). We
also observed an increase of efflux of manganese in
experimental models of hepatocarcinoma, resulting in
decreased content of metal (Galeotti et al., 1995). Thus, the
possibility remains that a decrease of dismutase activity in the
cells occurs during tumour transformation as a consequence
of various mechanisms, independently from the fate of
immunoreactive protein.
The second hypothesis originates from the fact that the
increase of immunoreactive protein is linked to the rise of
specific mRNA. As described above, both the redox state of
the cell itself and cytokines (mainly IL-1 and TNF-cx) are
involved in the regulation of the gene encoding for the
MnSOD (Hassan, 1988; Harris, 1992; Wong, 1995), and
autocrine and/or paracrine secretion of these cytokines by
glioblastomas or by the brain tissue surrounding the tumour
was reported (Nitta et al., 1994). Immunoreactive MnSOD
Table IV Correlation between MnSOD content, prognostic factors and survival
KPfr KPfP Residual Diameter Months of
No. MnSOD pre post R77 diseasec cm survival
24d 1 80 80 No Present 4 24 =
31 1 70 50 No Present 5 4alive
18 2 80 90 Yes Minimal 5 17alive
23 2 70 80 No Present 6 9alive
27 2 60 60 Yes Present 6 4=
28d 2 80 80 No Present 6.5 22=
30e 2 70 40 No Minimal 4 11 alive
20 3 80 80 Yes Minimal 2.5 16alive
25 3 80 60 Yes Minimal 3 7alive
19 4 70 50 Yes Minimal 6 13=
21 4 40 50 No Present 5.5 9=
22 4 60 40 No Present Multiple 1=
29 4 70 70 Yes Minimal 4 6alive
32 4 50 50 No Present 9 2alive
aKamowski performance index before (pre) and after(post) surgery.bPost-surgery radiotherapy.cResidual disease is
expressed with respect to tumour size before surgery: present > 10%; minimal< 10%. dPreoperative radiotherapy.
eBrachytherapy or preoperative radiotherapy. =deceased.xo'da MnSOD increase in brain tumours
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might therefore be only a sign of TNF-oc secretion. As we find
low levels of immunoreactive MnSOD in brain metastasis,
disregulation of TNF-ax gene expression occurring specifically
in glioblastomas possibly plays a prominent role (rather than
a non-tumour specific, 'proinflammatory' response of the
brain to an highly invasive neoplasm). As demonstrated by
the link between the levels of MnSOD and tumour grading,
this event of gene disregulation would be a late occurrence
during the neoplastic disease involved in tumour progression
rather than in the initiation step. Further research is currently
being undertaken to address these issues.
We observed low levels of immunoreactive MnSOD in
some ( 30%) of the glioblastomas that we studied. The
histological examination of adjacent slices excluded that this
finding was associated with necrotic or more differentiated
areas which are frequently present in multiform glioblasto-
mas. Biological and metabolic characteristics of those
glioblastomas that show this discrepancy will need to be
clarified in further research.
As mentioned in the introduction, a major problem that
neurosurgeons face is the attempt to highlight a population
of low-grade tumours that follow an accelerated clinical
course. The number of cases and the length of observation
period did not allow us to address this issue directly in grade
II or III tumours. However, our preliminary observations
convey the impression that 'lower' levels of MnSOD may be
related to longer survival within the group of patients
suffering from glioblastomas, although the data cannot be
processed by means of statistical analysis.
Thus, three observations support the proposal of a larger
study that will use the MnSOD content as a metabolic
marker of progression: (1) MnSOD increases with tumour
grading; (2) a very small number of grade II tumours (1/10)
display high levels of immunoreactive protein, in accordance
with the fact that only a few low-grade tumours have an
accelerated progression; (3) within a histologically defined
group, higher levels of MnSOD suggest a more elevated
aggressiveness of the disease.
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